论文部分内容阅读
伊鲁替尼(ibrutinib,1),化学名为1-[(3R)-3-[4-氨基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-d]-嘧啶-1-基]哌啶-1-基]-2-丙烯-1-酮,是美国Pharmacyclics公司和强生公司合作研发的布鲁顿酪氨酸激酶(BTK)抑制剂,美国FDA于2013年11月、2014年2月和7月先后批准其用于治疗既往接受至少一次治疗的套细胞淋巴瘤(MCL)、既往接受过一种药物治疗的慢性淋巴细胞白血病(CLL)
Ibrutinib (1), having the chemical name 1 - [(3R) -3- [4-phenoxyphenyl) -1H-pyrazolo [3,4- d ] -pyrimidin-1-yl] piperidin-1-yl] -2-propen-1-one is a Bruton tyrosine kinase (BTK) inhibitor developed by Pharmacyclics Company and Johnson & Johnson. In November 2013, February 2014 and July 2014, it was approved for the treatment of mantle cell lymphoma (MCL) who had previously received at least one treatment, Chronic Lymphocytic Leukemia (CLL) who had previously received one drug treatment,